Monday, April 18, 2016 - 15:00
  • First-in-class anti-MICA/B therapeutic antibody;

  • New data demonstrate dual mechanism of action of IPH4301, including tumor antigen targeting and immunomodulation;

  • IND-enabling studies starting in 2016.

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today presented a new set of preclinical data further validating the potential of its first-in-class anti-MICA/B antibody IPH4301 at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana, USA.

Poster #1491 reports that IPH4301, a humanized antibody, binds with high affinity to MICA/B and is a potent cytotoxic antibody, inducing direct tumor cell killing by ADCC. Moreover, an additional mode-of-action of the same antibody was revealed, whereby the antibody has the potential to overcome immunosuppression in tumors.

Among the highly immune-suppressive cell types in cancer are tumor-associated macrophages or myeloid-derived suppressor cells (MDSC), which can reduce NK and T cell activities. In vitro, IPH4301 could overcome immunosuppression by macrophages, restoring NK cell antibody-mediated killing to levels seen in the absence of suppressor macrophages. In addition, IPH4301 blocked MICA/B-induced down-modulation of NKG2D receptors on NK and CD8 T cells, thus disrupting a second immuno-suppressive mechanism. Finally, treatment with IPH4301 restored NK cell infiltration, prevented tumor growth and improved survival in different in vivo tumor models.

Nicolai Wagtmann, CSO of Innate Pharma, said: “We are enthusiastic about IPH4301 as a therapeutic candidate because of its dual mode of action, combining potent ADCC-mediated tumor killing with interesting immuno-modulating properties. The ability of IPH4301 to interfere with these immune-suppressive pathways, while at the same time retaining high direct ADCC potency, makes for a novel, unique proposition in the immune-oncology landscape. IND-enabling studies will start in 2016”.



Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma, will hold a conference call to the attention of analysts and portfolio managers to discuss the data published and Company’s innovative pipeline.

Time and dial in: Tuesday, April 19th 10:30am Eastern Time

USA: 888 504 7963

International: +1 719 325 2452

Access code: 1890466


PR in English82.77 KB
CP en français85.44 KB
Poster AACR 2016 on IPH4301534.58 KB